Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder

REFERENCES

• Sawyer MG, Rey JM, Graetz BW, Clark JJ, Baghurst PA. Use of medication by young people with attention‐deficit/hyperactivity disorder. Medical Journal of Australia 2002; 177: 21–25
   PubMed Web of Science ®Google Scholar
• Hazell PL, McDowell MJ, Walton JM. Management of children prescribed psychostimulant medication for attention deficit hyperactivity disorder in the Hunter region of NSW. Medical Journal of Australia 1996; 165: 477–480
   PubMed Web of Science ®Google Scholar
• Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry 1996; 35: 1314–1321
   PubMed Web of Science ®Google Scholar
• Kuperman S, Perry PJ, Gaffney GR, et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry 2001; 13: 129–134
   PubMedGoogle Scholar
• Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry 2001; 158: 282–288
   PubMed Web of Science ®Google Scholar
• Niederhofer H. An open trial of buspirone in the treatment of attention–deficit disorder. Human Psychopharmacology 2003; 18: 489–492
   PubMed Web of Science ®Google Scholar
• Otka JE, Mercadante MT, Scahill L, Leckman JF. Reboxetine as a potentially effective treatment for attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology 2001; 11: 203–204
   PubMed Web of Science ®Google Scholar
• Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in adults with attention‐deficit/hyperactivity disorder: an open clinical trial. Journal of Clinical Psychiatry 1996; 57: 184–189
   PubMed Web of Science ®Google Scholar
• Lyseng‐Williamson KA, Keating GM. Extended‐release methylphenidate (Ritalin LA). Drugs 2002; 62: 2251–2259
   PubMed Web of Science ®Google Scholar
• http://www.clinicalevidence.org, Ramchandani P, Joughin C, Zwi M. Attention deficit hyperactivity disorder. In: Godlee F. Clinical Evidence. BMJ Publishing, 2003
   Google Scholar
• Biederman J, Quinn D, Weiss M, et al. Methylphenidate hydrochloride extended‐ release capsules (Ritalin LA): a new once‐daily therapy for ADHD [Poster]. American Psychiatric Association, Annual Meeting, Philadelphia, PA, May, 18–232002
   Google Scholar
• Lopez F, Silva R, Pestreich L, Muniz R. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatric Drugs 2003; 5: 545–555
   PubMedGoogle Scholar
• Swanson J, Gupta S, Lam A, et al. Development of a new once‐a‐day formulation of methylphenidate for the treatment of attention‐deficit/hyperactivity disorder: proof‐ of‐concept and proof‐of‐product studies. Archives of General Psychiatry 2003; 60: 204–211
   PubMed Web of Science ®Google Scholar
• Pelham WE, Gnagy EM, Burrows‐Maclean L, et al. Once‐a‐day Concerta methyl‐ phenidate versus three‐times‐daily methylphenidate in laboratory and natural settings. Pediatrics 2001; 107: E105
   Google Scholar
• Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention‐deficit/hyperactivity disorder. Pediatrics 2001; 108: 883–892
   PubMed Web of Science ®Google Scholar
• Cox DJ, Merkel L, Penberthy JK, Kovatchev B, Hankin CL. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention‐deficit/hyper‐ activity disorder: a pilot study. Journal of the American Academy of Child and Adolescent Psychiatry 2004; 43: 269–275
   PubMed Web of Science ®Google Scholar
• Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. American Journal of Psychiatry 1998; 155: 693–695
   PubMed Web of Science ®Google Scholar
• Levy F, Farrow M. Working memory in ADHD: prefrontal/parietal connections. Current Drug Targets 2001; 2: 347–352
   PubMed Web of Science ®Google Scholar
• Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double‐blind placebo controlled study of desipramine in the treatment of ADD. I. Efficacy. Journal of the American Academy of Child and Adolescent Psychiatry 1989; 28: 777–784
   PubMed Web of Science ®Google Scholar
• Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostim‐ ulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry 2003; 42: 886–894
   PubMed Web of Science ®Google Scholar
• Michelson D, Allen AJ, Busner J, et al. Once‐daily atomoxetine treatment for chil‐ dren and adolescents with attention deficit hyperactivity disorder: a randomized, placebo‐controlled study. American Journal of Psychiatry 2002; 159: 1896–1901
   PubMed Web of Science ®Google Scholar
• Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled, dose‐response study. Pediatrics 2001; 108: E83
   PubMed Web of Science ®Google Scholar
• Caballero J, Nahata MC. Atomoxetine hydrochloride for the treatment of attention‐ deficit/hyperactivity disorder. Clinical Therapeutics 2003; 25: 3065–3083
   PubMed Web of Science ®Google Scholar
• Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo‐controlled studies. Biological Psychiatry 2003; 53: 112–120
   PubMed Web of Science ®Google Scholar
• Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof‐of‐concept, placebo‐controlled studies of atomoxetine in children with attention‐deficit/ hyperactivity disorder. Journal of Clinical Psychiatry 2002; 63: 1140–1147
   PubMed Web of Science ®Google Scholar
• Allen AJ, Milton DR, Michelson D, Kelsey DK. Efficacy of atomoxetine treatment for adolescents with attention‐deficit/hyperactivity disorder [Poster]. American Psychiatric Association, Annual Meeting, San Francisco, CA, May, 17–222003
   Google Scholar
• Biederman J, Heiligenstein JH, Faries DE, et al. Efficacy of atomoxetine versus placebo in school‐age girls with attention‐deficit/hyperactivity disorder. Pediatrics 2002; 110: E75
   PubMed Web of Science ®Google Scholar
• Michelson D, Zhang S, Buitelaar J, et al. Results from a long‐term trial of atomoxetine in the prevention of relapse in ADHD [Poster]. American Psychiatric Association, Annual Meeting, San Francisco, CA, May, 17–222003
   Google Scholar
• Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry 2002; 41: 776–784
   PubMed Web of Science ®Google Scholar
• Alderton HR. Tricyclic medication in children and the QT interval: case report and discussion. Canadian Journal of Psychiatry 1995; 40: 325–329
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. Journal of Clinical Psychiatry 2002; 63(Suppl.12)50–55
   PubMed Web of Science ®Google Scholar
• Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug and Alcohol Dependence 2002; 67: 149–156
   PubMed Web of Science ®Google Scholar